SaniMed Science Group Participates in TEN Capital Investor Education Series and Explores Follow-Up Opportunities with Emerging Healthcare Startups

July 7, 2026 — SaniMed Science Group Founder and CEO Jim Wu, M.D., MBA, participated as an investor panelist in the TEN Capital Investor Education Series, providing feedback to four emerging companies across medical technology, precision diagnostics, consumer wellness, and health-focused food innovation.

The virtual program brought together startup founders and investors for company presentations, interactive discussion, investor feedback, and targeted follow-up opportunities.

Representing SaniMed Science Group, Dr. Wu evaluated the participating companies from the perspectives of clinical value, technology differentiation, commercialization readiness, international expansion, strategic partnerships, and fundraising potential.

---

Connecting Startups with Relevant Investors

TEN Capital Network is an Austin-based fundraising and investor-connectivity platform that supports startups and growth companies through fundraising preparation, investor outreach, pitch events, strategic coaching, and investor introductions. Its programs are designed to reduce the time and operational burden associated with fundraising while improving the quality of engagement between founders and investors.

A notable feature of the Investor Education Series is its structured follow-up process.

Following the company presentations and investor commentary, participating investors are asked which companies they would like to explore further. TEN Capital can then facilitate direct introductions between interested investors and the relevant founders.

This approach helps move the conversation beyond a traditional pitch event and creates a more practical pathway toward follow-up meetings, strategic advice, commercial partnerships, and potential investment discussions.

---

Four Companies Presented During the Program

The July 7 program featured four companies representing different segments of the healthcare and wellness ecosystem.

ChillShark

ChillShark is developing an in-room recovery platform combining retrofit cold-therapy hardware, fleet software, and recovery intelligence.

The company is initially targeting luxury hospitality and recovery-oriented environments, seeking to provide cold-plunge functionality without requiring the installation of a new dedicated tub or major construction.

Its concept addresses some of the infrastructure, sanitation, operational, and space constraints that may limit the deployment of traditional cold-recovery systems in hotels and other hospitality settings.

Healthy For Life Foods / Jaca

Healthy For Life Foods presented Jaca, a consumer brand focused on allulose, a rare sugar positioned as an alternative to conventional sugar.

The company seeks to address increasing consumer demand for reduced-sugar and lower-calorie food options while maintaining a taste and usage experience that is closer to traditional sugar.

Jaca’s strategy combines consumer education, branded products, and the broader growth of the health-conscious food and beverage market.

Noleus Technologies

Noleus Technologies is developing the Noleus Leaf, a therapeutic medical device intended to help restart bowel function and accelerate recovery following abdominal surgery.

Postoperative bowel dysfunction can delay eating, prolong hospitalization, and increase the risk of complications. The Noleus Leaf is designed to be placed at the end of surgery and removed at the bedside after treatment.

The company believes that earlier restoration of bowel function could help patients begin eating and recovering sooner while potentially reducing hospital length of stay and associated costs.

Qualisure Diagnostics

Qualisure Diagnostics is developing an RNA-based precision oncology diagnostics platform designed to help physicians better understand the biological behavior of individual tumors.

The company’s first commercial product, Thyroid GuidePx®, is a transcriptomic prognostic test for papillary thyroid cancer. The test is intended to help physicians match treatment intensity more closely with the underlying biology and recurrence risk of a patient’s tumor.

Beyond its initial thyroid cancer product, Qualisure is building a broader platform for decentralized transcriptomic testing and clinical interpretation, with potential applications across additional cancers and treatment-selection decisions.

---

SaniMed Identifies Two Projects for Continued Evaluation

Following the presentations, SaniMed expressed interest in continuing discussions with Qualisure Diagnostics and Noleus Technologies.

Qualisure’s RNA-expression platform is relevant to the continued evolution of precision oncology beyond DNA-based mutation testing. Its combination of an existing commercial diagnostic product and a broader transcriptomic interpretation platform may create opportunities in clinical adoption, laboratory partnerships, international deployment, and cross-border commercialization.

Noleus addresses a significant and persistent problem in postoperative recovery. Further evaluation may focus on the company’s clinical evidence, regulatory pathway, device manufacturing, hospital adoption strategy, reimbursement model, and potential opportunities in international markets.

SaniMed’s follow-up process will consider not only the scientific and clinical potential of the two companies, but also their readiness for strategic partnerships, global market entry, and future financing.

---

Potential for Long-Term Collaboration Between SaniMed and TEN Capital

The event also highlighted the potential for broader collaboration between SaniMed Science Group and TEN Capital Network.

TEN Capital brings an established platform for startup fundraising preparation, investor engagement, pitching, and founder-investor introductions. SaniMed contributes experience in life sciences, medical technology, AI-enabled healthcare, regulatory strategy, commercialization, and cross-border market development across the United States and Asia.

Together, the two organizations may be able to support life science and healthcare startups in several areas:

· Strengthening investment narratives and pitch materials

· Improving investor and commercial readiness

· Evaluating clinical, regulatory, and commercialization strategies

· Connecting companies with relevant investors and strategic partners

· Exploring U.S., China, and broader Asian market opportunities

· Supporting cross-border licensing, partnerships, and fundraising

For healthcare startups, fundraising readiness requires more than an attractive presentation. Investors increasingly expect founders to demonstrate clinical relevance, differentiated technology, regulatory planning, market access, capital efficiency, and a realistic path to commercialization.

A combination of investor connectivity and sector-specific support can help emerging companies improve both their fundraising position and their ability to execute after capital is raised.

---